Prenetics Global Limited · NASDAQ:PRE

Prenetics Global — Q3 2026 Earnings Presentation

70 slides from Prenetics Global's earnings presentation, Nov 18, 2026

  1. Slide 1: Q3 2026 Investor Presentation

    1 Q3 2026 Investor Presentation 1

  2. Slide 2: Disclaimer

    Disclaimer This presentation has been prepared by Prenetics Global Limited (“Prenetics” or the “Company”) and is provided for informational purposes only in connection with the Company’s discussion of its Q3 2026 results. This presentation should be considered together with, and not in isolation fro

  3. Slide 3: Contents

    Contents Q3 2026 at a glance 04 Scorecard, return on acquisition marketing, guidance and the size of the opportunity I. Why IM8 wins 13 Product, science, brand, organization and capital II. Proof it works 21 Growth, independent data, retention, subscribers, acquisition cost, markets and pipeline III

  4. Slide 4: Q3 revenue grew 3.3x year over year to $64.1M

    Q3 2026 AT A GLANCE Q3 2026 SCORECARD Q3 revenue grew 3.3x year over year to $64.1M, above the top of guidance Record revenue, second straight quarter of lower CAC on increased spend, and a cash balance that grew while we did it. $64.1M Total revenue, +38% QoQ, ~3.3x YoY ~$284M +$4.1M $62.9M IM8 Ann

  5. Slide 5: $1 of acquisition marketing has returned $1.68, up from $1.44

    Q3 2026 AT A GLANCE GENERAL CATALYST’S COHORT TEST On General Catalyst’s test, $1 of acquisition marketing has returned $1.68, up from $1.44 Gross profit per $1 of acquisition marketing across the measured cohort book, at the 58% contractual gross margin in the General Catalyst agreement. $1.68 per

  6. Slide 6: Earliest 27,000 customers past 3x CAC in under two years

    Q3 2026 AT A GLANCE RETURN BY COHORT AGE Earliest 27,000 customers past 3x CAC in under two years, next 91,000 on pace for early 2027 Our own unit economics, at actual gross margin: the longer customers have been with us, the more each acquisition dollar has returned. 4.1x Past 3-to-1 in under two y

  7. Slide 7: We are choosing to invest more now, for five reasons

    Q3 2026 AT A GLANCE THE INVESTMENT DECISION We are choosing to invest more now, for five reasons It rests on the weight of the evidence, with one more quarter of it behind us. A large change, and our choice. The loss is the growth investment: $(30)–(35)M 2H 2026 Adjusted EBITDA loss now expected, ag

  8. Slide 8: The loss is our growth investment: before it, $30.6M in Q3

    Q3 2026 AT A GLANCE INVESTING FROM STRENGTH The loss is our growth investment: before it, the business earned $30.6M in Q3 Contribution Profit is what the business earns before acquisition marketing and brand partner costs. How much we invest on top of it is our decision. From Contribution Profit to

  9. Slide 9: Reaffirmed FY26 IM8 revenue guidance implies Q4 revenue of $73–80M

    Q3 2026 AT A GLANCE Q4 2026 OUTLOOK Reaffirmed FY26 IM8 revenue guidance of $215–222M implies Q4 IM8 revenue of $73–80M What reaffirmed FY guidance implies for Q4 — and what is deliberately not in these numbers. ~$46–53M of gross profit expected in Q4 Q4 Group revenue of $73–83M at ~63–64% margin ge

  10. Slide 10: ~$156M of FY2027's $400M+ guidance is projected from earlier cohorts

    Q3 2026 AT A GLANCE FY2027 GUIDANCE ~$156M of FY2027’s $400M+ guidance is projected from 2026 and earlier cohorts The FY2027 IM8 revenue target includes nothing from Hydration, nothing from Care Bears, nothing from any product we have not launched. ~$156M from 2026 and earlier cohorts The 11–18 oper

  11. Slide 11: IM8 holds 0.14% of a ~$200B global category

    Q3 2026 AT A GLANCE THE OPPORTUNITY IM8 holds 0.14% of a ~$200B global category At a ~$284M Annualized Revenue Run-Rate, IM8 is still under 1% of the category in every one of its five core markets. 0.14% 0.18% Share in the United States, IM8’s largest market: ~$121M of Annualized Revenue Run-Rate in

  12. Slide 12: A 1% share of the five core markets would be ~3x today's run-rate

    APPENDIX · DATA BOOK MARKET OPPORTUNITY A 1% share of the five core markets alone would be ~3x today’s run-rate Current share of a ~$200B global VMS category vs an illustrative 1% share of core markets (0.25% rest of world) MARKET TAM SHARE — TODAY VS ILLUSTRATIVE TARGET today target ARR — TODAY VS

  13. Slide 13: Why IM8 wins

    Why IM8 wins Proof it works The financial model 13

  14. Slide 14: Eight advantages reinforce each other, and together they are hard to copy

    I · WHY IM8 WINS EIGHT ADVANTAGES Eight advantages reinforce each other, and together they are hard to copy No single advantage explains the last twenty-two months. The system does — each one makes the other seven stronger. 1 Science that compounds 2 A brand people hand to people they love 3 Cohort

  15. Slide 15: Three core products, with quarterly plans 52–67% of each one's revenue

    I · WHY IM8 WINS PRODUCT Three core products, with quarterly plans 52–67% of each one’s revenue Daily Ultimate Essentials Pro Daily Ultimate Longevity The Beckham Stack All-in-one supplement with 90 nutrient-rich ingredients 10 clinically proven compounds scientifically formulated Daily Ultimate Ess

  16. Slide 16: One RCT completed and three underway, with two readouts by Q1 2027

    I · WHY IM8 WINS SCIENCE One RCT completed and three underway, with two readouts expected by Q1 2027 RCT-grade clinical evidence is rare in supplements. IM8 has one completed randomized controlled trial behind its core product — and three further randomized, placebo-controlled studies underway: two

  17. Slide 17: Every ambassador is a Prenetics shareholder

    I · WHY IM8 WINS Every ambassador is a Prenetics shareholder 2024 2025 2026 FEB 2026 APR 2026 MAY 2026 DEC 2024 · LAUNCH JUN 2025 Ollie Bearman Giannis Antetokounmpo Inter Miami CF David Beckham Aryna Sabalenka FORMULA 1 DRIVER NBA · 2× MVP MLS CLUB CO-FOUNDER, IM8 WORLD NO. 1 TENNIS One at launch,

  18. Slide 18: The NBA partnership opens nine markets with ~660 million people

    I · WHY IM8 WINS BRAND The NBA partnership opens nine markets with ~660 million people A multi-year league partnership announced October 12 in Hong Kong by David Beckham with NBA Asia — joined by two-time champion Chris Bosh. Nine markets · ~660 million people Australia, Brunei, Cambodia, Indonesia,

  19. Slide 19: IM8 runs on about 70 people: ~$3.1M of guided revenue per employee

    I · WHY IM8 WINS AI-NATIVE ORGANIZATION IM8 runs on about 70 people: ~$3.1M of guided revenue per employee IM8 produces more revenue per employee than any scaled brand in the category — and the gap widens as we grow. ~$2.6M ~70 IM8 employees delivering $215– 222M of guided FY2026 revenue 3.7x revenu

  20. Slide 20: General Catalyst funds up to 70% of acquisition marketing, cohort by cohort

    I · WHY IM8 WINS CAPITAL General Catalyst funds up to 70% of acquisition marketing, cohort by cohort CVF funds up to 70% of IM8's marketing spend 1 Deployed on a monthly cohort basis; IM8 retains full discretion over facility utilization. First funding executed at closing (July 14, 2026). Funded coh

  21. Slide 21: Proof it works

    Why IM8 wins Proof it works The financial model 21

  22. Slide 22: IM8 revenue has grown for six consecutive quarters, to $62.9M in Q3

    II · PROOF IT WORKS GROWTH IM8 revenue has grown for six consecutive quarters, to $62.9M in Q3 IM8 revenue by quarter since launch, $M. Q3 came in above the top of the $61.5–62.5M guided range. $62.9M guided $61.5–62.5M — beat the top $45.0M $33.8M $27.4M 11x in 18 months, six consecutive quarters o

  23. Slide 23: Independent card data and General Catalyst's underwriting support the model

    II · PROOF IT WORKS INDEPENDENT PROOF Independent card data and General Catalyst’s underwriting support the model Six outside measures of growth, customer quality and unit economics. The detail behind each is in the data book. INDA GA R I CA R D P A NE L · SH A R E INDA GA R I CA R D P A NEL · NEW D

  24. Slide 24: IM8 retains 11% of customers at month 23, 1.3x the next-best brand

    II · PROOF IT WORKS INDEPENDENT PROOF IM8 retains 11% of customers at month 23, 1.3x the next-best brand Share of customers still buying 22 months after their first purchase. IM8 · MONTH 23 Customers retained at month 23 · % of first-time buyers IM8 11.0% 11.0% of IM8 customers still buying nearly t

  25. Slide 25: Quarterly plans reached 61% of billings ten months after launch

    II · PROOF IT WORKS SUBSCRIPTION MIX Quarterly plans reached 61% of billings ten months after launch Share of monthly own-store billings by plan type. Quarterly (84-day) plans launched at scale in December 2025 and reached 60.9% of September 2026 total billings (65% of own-store). 0% → 61% in 10 mon

  26. Slide 26: Billings per customer rose 89% since launch, to $229 a month

    II · PROOF IT WORKS BILLINGS PER CUSTOMER Billings per customer rose 89% since launch, to $229 a month Own-store billings per unique billed customer per month (fully deduplicated) — up 89% since launch, driven by the shift to quarterly commitments. September: $229 per unique store customer. $121 → $

  27. Slide 27: The subscriber base reached ~160K and has grown every month on record

    II · PROOF IT WORKS SUBSCRIBERS The subscriber base reached ~160K and has grown every month on record Active subscriptions — ended September at roughly 160,000, with the base growing every single month on record. 175 156.1K 23K → 160K active subscribers Ended September at 156,112 subscribers (160,83

  28. Slide 28: CAC fell for a second straight quarter as spend rose to a record $39.3M

    II · PROOF IT WORKS ACQUISITION CAC fell for a second straight quarter as spend rose to a record $39.3M Blended CAC against monthly acquisition marketing. Spend rose again in Q3 — to a record $39.3M — and CAC fell 5%, the second consecutive decline. CAC ($ per new customer) Acquisition marketing spe

  29. Slide 29: More customers, cheaper: CAC fell 7% while spend rose 115%

    II · PROOF IT WORKS ACQUISITION More customers, cheaper: CAC fell 7% while spend rose 115% Quarterly new customers and blended Customer Acquisition Cost, 2026. Source: IM8 monthly cohort table; CAC = acquisition marketing ÷ new customers ($18.3M ÷ 59,942; $35.7M ÷ 118,493; $39.3M ÷ 137,892). Spend r

  30. Slide 30: About 52% of revenue comes from outside the US, across 46 countries

    II · PROOF IT WORKS GEOGRAPHY About 52% of revenue comes from outside the US, across 46 countries Share of IM8 revenue by market (Q3 2026). ~52% of IM8 revenue is generated outside the United States. All other (41 markets) 23.3% 46 countries shipped to as of Q3 2026 — with no single market other tha

  31. Slide 31: Three launches are planned for 2027, and none of them is in guidance

    II · PROOF IT WORKS PIPELINE Three launches are planned for 2027, and none of them is in guidance Every launch sells first into an active base of ~160,000 subscriptions whose acquisition cost is already paid — and none of this revenue is in our guidance. LIVE TODAY Q1 2027 Q2 2027 2027 Care Bears by

  32. Slide 32: Care Bears by IM8 takes the brand into retail in 1H 2027

    II · PROOF IT WORKS PIPELINE Care Bears by IM8 takes the brand into retail in 1H 2027 IM8's launch into retail, alongside direct-to-consumer: science-backed gummy multivitamins for kids and adults in 1H 2027, then better-for-you confectionery and kids' snacks. 01 · LAUNCHING 1H 02 · NEXT 03 · NEXT 2

  33. Slide 33: The financial model

    Why IM8 wins Proof it works The financial model 33

  34. Slide 34: Operating costs fell from 25% to 16% of revenue in two quarters

    III · THE FINANCIAL MODEL OPERATING LEVERAGE Operating costs fell from 25% to 16% of revenue in two quarters Cost lines and the Adjusted EBITDA loss as a percentage of revenue, Q1, Q2 and Q3 2026. Q1 2026 Q2 2026 Q3 2026 Operating costs: 25% → 17% → 16% Payments, people, R&D and other costs fell 9 p

  35. Slide 35: General Catalyst carried ~$19.9M of Q3's $39.3M acquisition marketing

    III · THE FINANCIAL MODEL CASH General Catalyst carried ~$19.9M of Q3’s $39.3M acquisition marketing Q3 2026 actuals: the quarter’s $39.3M of acquisition marketing, the contractual 70/30 split, and what was actually repaid — netting to the $31.6M in the AFCF reconciliation. Repayments track receipts

  36. Slide 36: Cash and current financial assets rose to $111.5M in a record marketing quarter

    III · THE FINANCIAL MODEL BALANCE SHEET Cash and current financial assets rose to $111.5M in a record marketing quarter ($ in thousands) Cash and cash equivalents Jun 30, 2026 59,050 Sep 30, 2026 63,436 $111.5M total cash + current financial assets at Sep Current financial assets 50,342 48,041 30: $

  37. Slide 37: $31.6M of net facility fundings covered the $27.5M cash used in operations

    III · THE FINANCIAL MODEL CASH FLOW $31.6M of net facility fundings covered the $27.5M cash used in operations Operating (incl. ~$9.8M inventory + prepayment build) Source: Unaudited condensed consolidated cash flows (Q2 2026 restated basis). Adjusted Free Cash Flow is a non-IFRS measure: net cash u

  38. Slide 38: Our long-term target is a 15–25% Adjusted EBITDA margin

    III · THE FINANCIAL MODEL LONG TERM FRAMEWORK Our long-term target is a 15–25% Adjusted EBITDA margin Recent quarters beside management’s long-term targets for each line, as a percentage of revenue. % of revenue Q1 2026 Q2 2026 Q3 2026 Long-term target Gross margin 65% 65% 64% 70–75% Operating costs

  39. Slide 39: Appendix: Data book

    Appendix Data book 39

  40. Slide 40: Definitions

    APPENDIX · DATA BOOK DEFINITIONS Definitions Operating metrics and non-IFRS measures used in this presentation, as defined in the Company’s Q3 2026 materials. See slide titled “Unaudited Non-IFRS Financial Measures” for more information. Annualized Revenue Run-Rate (ARR). Annualized Revenue Run-Rate

  41. Slide 41: Adjusted EBITDA margin improved 19 points in one quarter, to (20)%

    APPENDIX · DATA BOOK Q3 2026 CONSOLIDATED PRENETICS FINANCIAL RESULTS Adjusted EBITDA margin improved 19 points in one quarter, to (20)% PRE consolidated ($M · % of revenue) Q1 2026 Q2 2026 Q3 2026 QoQ Revenue $36.0M $46.5M $64.1M +38% LEVERAGE IS EXPANDING IN MULTIPLE AREAS Gross profit $23.3M $30.

  42. Slide 42: Operating outflow of $27.5M; loss includes $40.0M of acquisition marketing

    APPENDIX · DATA BOOK STATEMENT OF CASH FLOWS Operating outflow of $27.5M. Loss for period includes $40.0M of acquisition marketing Condensed cash flows ($000) Q2 2026 Q3 2026 THE OPERATING LINE IS THE ACQUISITION INVESTMENT Loss for the period (8,980) (25,415) Q3 operating outflow of $(27.5)M carrie

  43. Slide 43: Monthly revenue reached $23.7M in 22 months

    APPENDIX · DATA BOOK GROWTH Monthly revenue reached $23.7M in 22 months ~$284M Annualized Revenue Run-Rate (September 2026) ~21% compounded monthly growth over 22 months; September was the strongest month and largest new-customer cohort in company history. Note: Monthly revenue is derived from the C

  44. Slide 44: Quarterly plans are now the largest revenue line, at $15.4M a month

    APPENDIX · DATA BOOK THE SUBSCRIPTION ENGINE Quarterly plans are now the largest revenue line, at $15.4M a month Own-store billings by plan type (marketplaces, ~6% of total billings and almost entirely one-time, excluded). The stack keeps rising while its composition shifts decisively toward longer

  45. Slide 45: A quarterly order collects ~$328 up front, 2.6x a monthly order

    APPENDIX · DATA BOOK THE SUBSCRIPTION ENGINE A quarterly order collects ~$328 up front, 2.6x a monthly order Own-store billings per order by plan type, September 2026. A quarterly order collects ~2.6x a monthly cycle at the point of sale. Cash pulled forward Three cycles of cash arrive on day one. A

  46. Slide 46: Recurring plans were 93% of own-store billings in September

    APPENDIX · DATA BOOK THE SUBSCRIPTION ENGINE Recurring plans were 93% of own-store billings in September Recurring plans (monthly + quarterly + bi-monthly) as a share of own-store billings (93% in September); ~88% of total billings including marketplaces, per the Q3 shareholder letter. Predictable b

  47. Slide 47: ~94% of IM8 revenue flows through its own store

    APPENDIX · DATA BOOK THE SUBSCRIPTION ENGINE ~94% of IM8 revenue flows through its own store Channel mix of gross revenue, monthly through September 2026. The customer relationship, data, and margin stay first-party; marketplaces are incremental reach, not dependency. Owned-store economics No market

  48. Slide 48: The first order now covers about 73% of acquisition cost

    APPENDIX · DATA BOOK UNIT ECONOMICS The first order now covers about 73% of acquisition cost New-customer acquisition cost matched against the first-order value of all new customers · updated through Q3 2026. CAC (Acquisition marketing spend ÷ new customers) All-customer AOV (first-order value) Q2–Q

  49. Slide 49: Every listed market grew at least 1.8x year over year

    APPENDIX · DATA BOOK GEOGRAPHIC MIX Every listed market grew at least 1.8x year over year Country Q3 2025 Q2 2026 Q3 2026 % of Q3'26 YoY QoQ United States $6.5M $20.3M $29.7M 48.1% 4.6x +47% Canada $2.6M $6.3M $8.4M 13.5% 3.3x +33% United Kingdom $2.5M $3.6M $4.6M 7.4% 1.8x +25% Australia $0.9M $2.5

  50. Slide 50: IM8's share of the four-brand set rose from 1% to 16%

    APPENDIX · DATA BOOK INDEPENDENT CARD DATA IM8’s share of the four-brand set rose from 1% to 16% IM8's share of combined monthly sales across IM8, AG1, Grüns and Thorne. IM8 SHARE · SEP '26 IM8 share of greens incumbents · monthly 20% 16% of greens-incumbent sales, up from 1% in Jan 15% '25 Jan '25

  51. Slide 51: IM8 is growing ~10x faster than the next-fastest brand

    APPENDIX · DATA BOOK INDEPENDENT CARD DATA IM8 is growing ~10x faster than the next-fastest brand Year-to-date sales growth, Jan–Sep 2026 vs the same period in 2025. IM8 · YTD 2026 YTD sales growth · Jan–Sep '26 vs Jan–Sep '25 IM8 +348% +348% vs +36% for Thorne, the fastest-growing incumbent Thorne

  52. Slide 52: IM8 customers spend ~2x the nearest competitor

    APPENDIX · DATA BOOK INDEPENDENT CARD DATA IM8 customers spend ~2x the nearest competitor IM8 tracked AG1, Grüns and Thorne until Sep '25, then pulled away every month since. Competitors are flat or falling. Average transaction value · monthly, USD Sales per customer · monthly, USD $192 1.9x AG1 · 2

  53. Slide 53: 87% of new IM8 buyers had not bought the three rivals

    APPENDIX · DATA BOOK INDEPENDENT CARD DATA 87% of new IM8 buyers had not bought the three rivals Prior purchases at each competitor among new IM8 customers, before their first IM8 order. NEW TO THE COMPETITIVE SET Where new IM8 customers came from · % of new customers 87% IM8 brings new buyers into

  54. Slide 54: IM8 buyers are up to 24x more likely to shop fitness brands

    APPENDIX · DATA BOOK INDEPENDENT CARD DATA IM8 buyers are up to 24x more likely to shop fitness brands How much more likely IM8 customers are to shop each brand than the average US card consumer. Relative affinity of IM8 customers · x vs average US card consumer Tracksmith (running) 24.2x WHOOP 19.6

  55. Slide 55: 52% of IM8 customers have $150K+ household income

    APPENDIX · DATA BOOK INDEPENDENT CARD DATA 52% of IM8 customers have $150K+ household income, 10 points above peers Card-panel income mix shows IM8 with the most affluent customer base in the category % OF CUSTOMERS WITH HOUSEHOLD INCOME $150K+ SCIENCE, CLINICAL EVIDENCE & CERTIFICATION 95% 85% 80%

  56. Slide 56: Cohort financing funds growth without dilution or fixed repayments

    APPENDIX · DATA BOOK GENERAL CATALYST PARTNERSHIP Cohort financing funds growth without dilution or fixed repayments Acquisition is paid on day one; cohort gross profit arrives over the customer lifetime. That gap is what limits every high-growth consumer brand. The historical choice The cohort-fina

  57. Slide 57: The facility costs 4.7–7.6% on projected payback, never more than 17%

    APPENDIX · DATA BOOK GENERAL CATALYST PARTNERSHIP The facility costs 4.7–7.6% on projected payback, and never more than 17% G C ' S P R E M I U M , B Y P A Y B A C K S P E E D ** Fund the month's customer growth, treated as a financial liability 1 GC provides up to 70% of what IM8 elects to fund of

  58. Slide 58: The facility does not touch revenue, gross margin or Adjusted EBITDA

    APPENDIX · DATA BOOK GENERAL CATALYST PARTNERSHIP The facility does not touch revenue, gross margin or Adjusted EBITDA Q3 2026 condensed financials with every General Catalyst touchpoint marked ● The facility's entire footprint is two lines — borrowings on the balance sheet and interest expense belo

  59. Slide 59: General Catalyst's $1B funds an illustrative path to $1B ARR by Q2 2029

    APPENDIX · DATA BOOK PATH TO SCALE ILLUSTRATIVE — NOT FINANCIAL GUIDANCE General Catalyst’s $1B funds an illustrative path to $1B ARR by Q2 2029 SPEND & GROWTH TO EVENTUALLY DECOUPLE Even as spend is deliberately held flat at the ~$60M/mo ceiling from 2028, the bars stop growing, but the revenue lin

  60. Slide 60: A Mayo Clinic trial is testing IM8 against placebo in 100 healthcare workers

    APPENDIX · DATA BOOK CLINICAL EVIDENCE · MAYO CLINIC · IM8 DAILY ULTIMATE ESSENTIALS A Mayo Clinic trial is testing IM8 against placebo in 100 healthcare workers A randomized, placebo-controlled trial of Daily Ultimate Essentials in healthcare workers — investigator-initiated, run at Mayo Clinic in

  61. Slide 61: The Longevity trial: 180 people, 90 days, results by Q1 2027

    APPENDIX · DATA BOOK CLINICAL EVIDENCE The Longevity trial: 180 people, 90 days, results expected by Q1 2027 Designed to generate independently defensible clinical evidence across aging-related health domains — metabolic health, systemic inflammation, autonomic function, sleep, and wellbeing. DESIGN

  62. Slide 62: The Gut Health trial: 135 people, 8 weeks, results by Q1 2027

    APPENDIX · DATA BOOK CLINICAL EVIDENCE The Gut Health trial: 135 people, 8 weeks, results expected by Q1 2027 Designed to generate independently defensible evidence across four gut-health domains — microbiome composition, inflammatory markers, metabolic proxies, and digestive comfort. DESIGN Randomi

  63. Slide 63: Nine scientific and medical advisors across six disciplines

    APPENDIX · DATA BOOK SCIENTIFIC ADVISORS Nine scientific and medical advisors across six disciplines Oncology, microbiome, sports medicine, regenerative medicine, cardiovascular research, and space biology Dr. Dawn Mussallem Dr. James L. Green Prof. Suzanne Devkota Dr. James DiNicolantonio Dr. Pamel

  64. Slide 64: 200+ activations in 20+ cities have put 100K+ samples in customers' hands

    APPENDIX · DATA BOOK 200+ activations in 20+ cities have put 100K+ samples in customers’ hands Shows Up in Person and Four Flagship Moments put in Front Creates a Sense of Community of World’s Health-Conscious Audience MIAMI CALIFORNIA WIMBLEDON · LONDON AUSTRALIA OPEN · MELBOURNE Recovery + trainin

  65. Slide 65: Customers now want one full daily regimen, and IM8 was built for it

    APPENDIX · DATA BOOK CATEGORY EVOLUTION Customers now want one full daily regimen, and IM8 was built for it Each generation reset what customers pay for — IM8 is built natively for the third SUPPLEMENTS 1.0 SUPPLEMENTS 2.0 SUPPLEMENTS 3.0 Price-led retail Single-function DTC Proprietary, full-stack,

  66. Slide 66: Only IM8 combines clinical evidence, brand and a complete daily system

    APPENDIX · DATA BOOK COMPETITIVE POSITIONING Only IM8 combines clinical evidence, brand and a complete daily system Three dimensions — form factor, clinical evidence on the finished formula, and what the brand leads with. IM8 is alone at the integrated corner. 1 · FORM FACTOR What the customer actua

  67. Slide 67: Six adjacent categories are under exploration, with none yet committed

    APPENDIX · DATA BOOK PIPELINE & WHITESPACE Six adjacent categories are under exploration, with none yet committed A customer who hands our sachet to someone they love would trust us in any category where science and quality decide the winner. That map is most of consumer health — and IM8 is twenty-t

  68. Slide 68: One of 830 US-listed consumer and healthcare companies passes this screen

    APPENDIX · DATA BOOK PEER SCREEN One of 830 US-listed consumer and healthcare companies passes this screen Screening every US-listed consumer and healthcare company on scale, margin and growth leaves exactly one name PUBLICLY LISTED Major U.S. exchange — Consumer Staples, Consumer Discretionary and

  69. Slide 69: PRE consolidated: reconciliation of non-IFRS measures

    APPENDIX · DATA BOOK NON-IFRS RECONCILIATION PRE consolidated: reconciliation of non-IFRS measures Adjusted EBITDA Reconciliation ($M) Q1 2026 Q2 2026 Q3 2026 Loss for the period (IFRS) (23.1) (9.0) (25.4) Depreciation & amortization, interest & tax, net (0.1) (0.1) 0.5 EBITDA (23.2) (9.1) (24.9) Eq

  70. Slide 70: Unaudited Non-IFRS Financial Measures

    Unaudited Non-IFRS Financial Measures To supplement the Company’s consolidated financial statements prepared in accordance with International Financial Reporting Standards (IFRS), the Company is providing the following non-IFRS measures: EBITDA, Adjusted EBITDA, Adjusted EBITDA Margin, Contribution

Prenetics Global — Q3 2026 Earnings Presentation on 6ix